TRUE Private Wealth Advisors bought a new stake in Danaher Co. (NYSE:DHR) in the second quarter, HoldingsChannel reports. The fund bought 664 shares of the conglomerate’s stock, valued at approximately $95,000.
Other institutional investors also recently added to or reduced their stakes in the company. Jennison Associates LLC purchased a new stake in Danaher during the first quarter worth approximately $489,930,000. Janus Henderson Group PLC grew its stake in Danaher by 274.8% during the second quarter. Janus Henderson Group PLC now owns 2,858,029 shares of the conglomerate’s stock worth $408,466,000 after buying an additional 2,095,396 shares during the period. Railway Pension Investments Ltd purchased a new stake in Danaher during the second quarter worth approximately $13,030,000. Marshall Wace North America L.P. grew its stake in Danaher by 48.5% during the first quarter. Marshall Wace North America L.P. now owns 2,115,438 shares of the conglomerate’s stock worth $279,281,000 after buying an additional 690,837 shares during the period. Finally, Geode Capital Management LLC grew its stake in Danaher by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 7,527,142 shares of the conglomerate’s stock worth $774,743,000 after buying an additional 583,194 shares during the period. Hedge funds and other institutional investors own 79.35% of the company’s stock.
Several equities research analysts have issued reports on DHR shares. Robert W. Baird boosted their price objective on shares of Danaher from $131.00 to $148.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Piper Jaffray Companies boosted their price objective on shares of Danaher from $148.00 to $153.00 and gave the stock a “neutral” rating in a research note on Thursday, July 18th. Zacks Investment Research upgraded shares of Danaher from a “sell” rating to a “hold” rating in a research note on Monday, May 6th. Argus boosted their price objective on shares of Danaher to $165.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Finally, Royal Bank of Canada set a $134.00 price objective on shares of Danaher and gave the stock a “hold” rating in a research note on Friday, July 19th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $143.54.
Danaher (NYSE:DHR) last announced its earnings results on Thursday, July 18th. The conglomerate reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.04. The business had revenue of $5.16 billion during the quarter, compared to the consensus estimate of $5.09 billion. Danaher had a net margin of 12.22% and a return on equity of 11.53%. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.15 earnings per share. Equities analysts expect that Danaher Co. will post 4.79 earnings per share for the current year.
In other news, SVP William King sold 12,950 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $129.92, for a total value of $1,682,464.00. Following the completion of the transaction, the senior vice president now directly owns 29,070 shares in the company, valued at $3,776,774.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian W. Ellis sold 1,010 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $144.04, for a total transaction of $145,480.40. Following the completion of the transaction, the insider now owns 20,889 shares of the company’s stock, valued at $3,008,851.56. The disclosure for this sale can be found here. Insiders sold 361,850 shares of company stock valued at $49,587,520 over the last 90 days. Insiders own 11.40% of the company’s stock.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Read More: Leveraged Buyout (LBO)
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.